Skip to content

Macroplastique Implants

by Uroplasty, LLC

PMA P040050

Active United States

PMA

Valid until

No expiry

PMA approval is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

PMA P040050↗

FDA record

Trust

Unverified

Source FDA PMA, synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPPR Approved NumberP040050 Date30 Oct 2006ApprovedStatusActive

Official records

From the FDA record

FDA PMA P040050

Received by the FDA
22 Dec 2004
FDA decision
30 Oct 2006
FDA review time
677 days from receipt to decision
Docket number
06M-0457
Approval order statement, verbatim
APPROVAL FOR MACROPLASTIQUE IMPLANTS. THE DEVICE IS INDICATED FOR TRANSURETHRAL INJECTION IN THE TREATMENT OF ADULT WOMEN DIAGNOSED WITH STRESS URINARY INCONTINENCE (SUI) PRIMARILY DUE TO INTRINSIC SPHINCTER DEFICIENCY (ISD).

From the FDA PMA record P040050 (openFDA), as read on 22 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA PMA Active

Specification

PMA

Generic name
AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE
PMA number
FDA product code
LNM
Device class
Class III
Advisory committee
Gastroenterology, Urology
FDA decision
APPR Approved

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

Macroplastique Implants are an injectable bulking agent designed for gastro-urology use. This medical device is indicated for transurethral injection in adult women who have been diagnosed with stress urinary incontinence primarily due to intrinsic sphincter deficiency.

This device is manufactured by Uroplasty, LLC and has received FDA premarket approval. It is intended for clinical use by medical professionals to address specific urological conditions in female patients.

Devices cleared under P040050

1 device · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under P040050
UDI-DISize and differences
Macroplastique Implants MPQ-2.5
Uroplasty, LLC
MPQ-2.5 / MPQ-2.508717591240266 —On the market

Similar devices

Other devices filed under FDA product code LNM (Agent, Bulking, Injectable For Gastro-Urology Use).

Other devices from Uroplasty, LLC

See all devices from Uroplasty, LLC →

Questions

AI-generated answers, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What is the primary use of Macroplastique Implants?

    Macroplastique Implants are used as an injectable bulking agent for the treatment of stress urinary incontinence in adult women, specifically when the condition is caused by intrinsic sphincter deficiency.

  • How are Macroplastique Implants administered?

    The device is administered via transurethral injection by a qualified medical professional to provide the necessary bulking effect for treating incontinence.

  • Who manufactures Macroplastique Implants?

    Macroplastique Implants are manufactured by Uroplasty, LLC, based in Minnetonka, Minnesota.